Effective October 2017, Kv1.3 Therapeutics, Inc. began to issue external communications and press releases.
Previous press releases from KPI Therapeutics, Inc are included for information.
Press Releases
-
New Data Supports Dalazatide from Kv 1.3 Therapeutics as a Potential Therapy for Inclusion Body Myositis (IBM)
April 25, 2018 by KV1.3 Therapeutics
-
Craig W. Philips Appointed Interim CEO of Kv1.3 Therapeutics, Inc.
October 21, 2017 by Kv1.3 Therapeutics
-
Kv1.3 Therapeutics Presents New, Published Data in Myositis Demonstrating the Presence of Kv1.3 Channels at the Site of the Muscle Damage Caused by Autoimmune Inflammatory Response
October 19, 2017 by Kv1.3 Therapeutics
-
KPI Therapeutics Presents New Dalazatide Data Again Demonstrating Positive Response in Lupus
May 22, 2017 by KPI Therapeutics
-
KPI Therapeutics Presents Updated, Positive Data Demonstrating Efficacy of KPI-150 Against Atopic Dermatitis
April 27, 2017 by KPI Therapeutics
-
KPI Therapeutics Presents New Positive Data Demonstrating Efficacy of KPI-150 Against Atopic Dermatitis
November 16, 2016 by KPI Therapeutics
-
KPI Therapeutics Invited to Present Positive Data on KPI-150 as a Potential New Therapy for Atopic Dermatitis at Skin Disease Conference
October 27, 2016 by KPI Therapeutics
-
Alliance for Children’s Therapeutics (ACT) Presents Dalazatide Data Demonstrating Positive Response in Lupus
June 10, 2016 by KPI Therapeutics
-
KPI Therapeutics’ BIO Presentation to Highlight First Clinical Development Success of Kv 1.3 Inhibitor Dalazatide in Autoimmune Diseases
June 2, 2016 by KPI Therapeutics
-
KPI Therapeutics to Present Updated Dalazatide Study Data in Lupus
May 23, 2016 by KPI Therapeutics
-
KPI Therapeutics Presents Dalazatide Plaque Psoriasis Data at Dermatology Conference
May 12, 2016 by KPI Therapeutics
-
KPI Therapeutics to Present Dalazatide Plaque Psoriasis Data at Dermatology Conference
April 18, 2016 by KPI Therapeutics
-
KPI Therapeutics Presents Promising Data on KPI-190 as Potential Therapy for Uveitis, Autoimmune Eye Diseases
March 21, 2016 by KPI Therapeutics
-
KPI Therapeutics to Present Dalazatide Data as Potential Therapy for Uveitis, Autoimmune Eye Diseases at Ocular Conference
March 14, 2016 by KPI Therapeutics
-
KPI Therapeutics Announces Expanded Drug Programs in Eye and Skin Diseases
February 8, 2016 by KPI Therapeutics
-
University of Washington, Kineta, KPI form alliance to advance discoveries to bring new therapeutics to market
April 21, 2015 by KPI Therapeutics
News
-
Dalazatide featured in National TV healthcare story
March 8, 2017 from Fox 26 Houston
-
Arthritis Research Foundation Video Highlights Dalazatide
September 15, 2016 from Arthritis National Research Foundation
-
Lupus drug moves forward, DDNEWS
August 1, 2016 from DDNews
-
Dalazatide Shows Promise in Early Lupus Study, Lupus News Today
June 16, 2016 from Lupus News Today
-
Sea Anemone Venom Shows Promise For Lupus Immunotherapy Treatment
June 10, 2016 from Seattle Childrens